A Phase 2 interventional study of NNC0662-0419 and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 233 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner.
Drug: NNC0662-0419
Participants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner.
Drug: NNC0662-0419 Placebo
Participants will receive semaglutide administered subcutaneously in a dose-escalation manner.
Drug: Semaglutide
Participants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner.
Drug: Semaglutide placebo
NNC0662-0419 will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Placebo matched to NNC0662-0419 will be administered subcutaneously.
Placebo matched to semaglutide will be administered subcutaneously.
Number of gastrointestinal adverse events
Measured as number of events.
Time frame: From week 0 to week 39
Relative change in body weight
Measured as percentage (%) change.
Time frame: From week 0 to week 32
Change in body mass index (BMI)
Measured as kilogram per square meter (kg/m\^2).
Time frame: From week 0 to week 32
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S